Does diabetic peripheral neuropathic pain (DPNP) disrupt your daily life and keep you awake at night despite your current treatment? You are not alone. The NEPTUNE-17 clinical trial, hosted by the Foundation for Peripheral Neuropathy Research Impact’s partner, GSK, offers a potential new option for managing DPNP symptoms.
- The NEPTUNE-17 study is a clinical trial focused on assessing how well a new investigational drug can reduce pain and its safety for individuals suffering from DPNP. This study aims to evaluate how it can reduce pain and improve the quality of life for those affected by this condition.
You may be eligible to participate in the trial if you:
- Are 18 to 75 years of age
- Have been diagnosed with Type I or Type II diabetes with DPNP for at least the past 6 months
- Still have diabetic nerve pain despite current or previous drug treatments
You will also need to meet additional requirements; the study doctor will review these with you.
- By joining the NEPTUNE-17 study, you can contribute to important medical research that could lead to more effective treatments for DPNP. Participants may also receive study-related medical care and investigational treatment at no cost.
How to learn more
For more detailed information about the study and to see if you may qualify, visit NEPTUNE-17 Study.
Please note that this website is available in the US, Canada, France, South Africa, and Spain. (as of 7.23.24)